Acer Therapeutics Inc.

OTCPK:ACER Stok Raporu

Piyasa değeri: US$19.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Acer Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Acer Therapeutics CEO'su Chris Schelling, Dec2013 tarihinde atandı, in görev süresi 9.92 yıldır. in toplam yıllık tazminatı $ 834.28K olup, şirket hissesi ve opsiyonları dahil olmak üzere 59.9% maaş ve 40.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 11.09% ine doğrudan sahiptir ve bu hisseler $ 2.18M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.2 yıl ve 6.2 yıldır.

Anahtar bilgiler

Chris Schelling

İcra Kurulu Başkanı

US$834.3k

Toplam tazminat

CEO maaş yüzdesi59.93%
CEO görev süresi9.9yrs
CEO sahipliği11.1%
Yönetim ortalama görev süresi4.2yrs
Yönetim Kurulu ortalama görev süresi6.2yrs

Son yönetim güncellemeleri

Analiz Makalesi • Feb 25

Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...

Recent updates

Seeking Alpha • Oct 05

Acer Therapeutics to develop ACER-801 for post-traumatic stress disorder treatment

Acer Therapeutics (NASDAQ:ACER) said on Wednesday it was expanding ACER-801 into a new indication, to reduce the frequency and severity of acute stress disorder and post-traumatic stress disorder. (ACER) is trading 3.5% higher premarket. In a study conducted in thousands of genes that were activated in the brains of mice following fear conditioning events showed the drug was able to block fear memory consolidation shortly after exposure to a trauma. ACER-801 is a non-hormonal drug designed as a selective non-peptide neurokinin 3 receptor (NK3R) antagonist. "While the role of the NK3R pathway in the hypothalamus to manage thermoregulation is well-established in clinical trials, this opportunity explores an entirely different mechanism of action for the drug. We look forward to presenting our clinical development plan for ACER-801 for the reduction of frequency and severity of PTSD in the near future," the company said. Acute stress disorder refers to the body’s immediate response to trauma, whereas PTSD is defined as the long-term effects of trauma. The company is also developing the drug for induced Vasomotor Symptoms, which is hot flashes, flushing, and night sweats — that tend to occur in or around menopause.
Seeking Alpha • Aug 12

Acer, Relief's metabolic disorder therapy ACER-001 gets orphan drug status in EU

The European Commission granted orphan medicinal product designation to Acer Therapeutics (NASDAQ:ACER) and Relief Therapeutics' (OTCQB:RLFTF) (OTCQB:RLFTY) ACER-001 (sodium phenylbutyrate) to treat patients with Maple Syrup Urine Disease (MSUD). ACER-001 was had received the U.S. Food and Drug Administration's (FDA) orphan drug designation for MSUD in 2014, the companies said in an Aug. 12 press release. MSUD is a rare genetic metabolic disorder characterized by deficiency of an enzyme complex which is required to break down certain amino acids in the body. In the EU, the orphan drug status is granted to therapies aimed at treating or preventing a serious or life-threatening disease which affects not more than five in 10K people in the EU. The designation has benefits, including up to 10 years of market exclusivity for the product, if approved. ACER +6.76% to $1.58 premarket Aug. 12
Seeking Alpha • Jul 28

FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy

Acer Therapeutics (NASDAQ:ACER) and partner Relief Therapeutics (OTCQB:RLFTF) (OTCQB:RLFTY) on Thursday said the U.S. Food and Drug Administration (FDA) had accepted the companies' resubmission of their new drug application for their ACER-001 treatment for patients with urea cycle disorders. The FDA designated the new drug application (NDA) as a class 2 resubmission and said it would review the application by Jan. 15, 2023, or the so-called Prescription Drug User Fee Act date. Despite the news, ACER stock had fallen 4.2% to $1.37 in premarket trading. The FDA's acceptance of the NDA comes 10 days after ACER and RLFTF resubmitted the application. The NDA had been initially declined by the FDA in June as the agency's field investigator had been unable to complete inspection of ACER's third-party contract packaging manufacturer.
Seeking Alpha • Jul 18

Acer resubmits U.S. marketing application for urea cycle disorder therapy

Newton, Massachusetts-based Acer Therapeutics (NASDAQ:ACER) announced on Monday that the company resubmitted its New Drug Application (NDA) seeking FDA approval of ACER-001 oral suspension for the treatment of patients with urea cycle disorders (UCDs). Also known as sodium phenylbutyrate, ACER-001 is undergoing studies as a treatment for various inborn errors of metabolism such as UCDs. In June, Acer (ACER) announced that the FDA issued a Complete Response Letter (CRL), rejecting the marketing approval of the drug, citing the need for satisfactory inspection of its third-party contract packaging manufacturer. In the resubmission, the company has informed the FDA that the contract manufacturer in question is ready for inspections. In addition to labeling and other standard updates to the original filing, the resubmitted NDA included the nonclinical info that the FDA requested but categorized as “not an approvability issue” in the CRL. A decision on the acceptance of the NDA is expected within 14 calendar days of the submission. Last month, the shares of Acer (ACER) and its partner Relief Therapeutics (OTCQB:RLFTF) fell on the announcement of FDA rejection of ACER-001.
Analiz Makalesi • Feb 11

Companies Like Acer Therapeutics (NASDAQ:ACER) Can Afford To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Aug 31

Acer Therapeutics: Deriving Value By Developing Therapies For Rare Diseases

Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious, rare, and life-threatening diseases. Acer submitted an NDA for its lead drug candidate ACER-001 for treatment of UCDs in early August. Acer expects notification regarding potential acceptance for filing from the FDA approximately 60 days after NDA submission and subsequent substantive review. If approved, Acer could launch ACER-001 in mid-2022. Other than UCDs, Acer is developing therapies for MSUD, iVMS, vEDS, and infectious diseases. All these diseases have a market that is niche and untapped, characterized by low competition. Assuming a base case revenue of $40 million in 2022 and a P/S ratio of 5.0x, the company’s intrinsic value would be ~$122 million or $8.70 per share, indicating an upside close to 3.5x.
Analiz Makalesi • May 20

We're Not Very Worried About Acer Therapeutics' (NASDAQ:ACER) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analiz Makalesi • Feb 25

Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...

CEO Tazminat Analizi

Chris Schelling'un ücretlendirmesi Acer Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2023n/an/a

-US$39m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$834kUS$500k

-US$26m

Sep 30 2022n/an/a

-US$21m

Jun 30 2022n/an/a

-US$20m

Mar 31 2022n/an/a

-US$20m

Dec 31 2021US$552kUS$436k

-US$15m

Sep 30 2021n/an/a

-US$17m

Jun 30 2021n/an/a

-US$20m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$676kUS$436k

-US$23m

Sep 30 2020n/an/a

-US$22m

Jun 30 2020n/an/a

-US$21m

Mar 31 2020n/an/a

-US$26m

Dec 31 2019US$1mUS$436k

-US$29m

Sep 30 2019n/an/a

-US$33m

Jun 30 2019n/an/a

-US$31m

Mar 31 2019n/an/a

-US$25m

Dec 31 2018US$550kUS$400k

-US$21m

Sep 30 2018n/an/a

-US$17m

Jun 30 2018n/an/a

-US$17m

Mar 31 2018n/an/a

-US$15m

Dec 31 2017US$585kUS$117k

-US$14m

Sep 30 2017n/an/a

-US$12m

Jun 30 2017n/an/a

-US$11m

Mar 31 2017n/an/a

-US$9m

Dec 31 2016US$469kUS$469k

-US$7m

Tazminat ve Piyasa: Chris 'ın toplam tazminatı ($USD 834.28K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 653.62K ).

Tazminat ve Kazançlar: Chris şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Chris Schelling (47 yo)

9.9yrs
Görev süresi
US$834,280
Tazminat

Mr. Christopher Schelling, also known as Chris, Founded Acer Therapeutics Inc. in December 2013 and has been its President and Chief Executive Officer since September 2017 and served as its Chief Operating...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Christopher Schelling
Founder9.9yrsUS$834.28k11.09%
$ 2.2m
Harry Palmin
Chief Financial Officer7.8yrsUS$592.59k0.51%
$ 100.6k
Adrian Quartel
Chief Medical Officer1.8yrsUS$857.63k0%
$ 0
Tanya Hayden
Chief Operating Officer1.4yrsVeri yokVeri yok
John Klopp
Chief Technical Officer4.2yrsVeri yokVeri yok
Donald Joseph
Chief Legal Officer & Secretary5.6yrsUS$490.28kVeri yok
Bernie Paul
Chief People Officer3.1yrsVeri yokVeri yok
Jefferson Davis
Chief Business Officer2.8yrsUS$634.80k0.29%
$ 57.6k
Jason Kneeland
VP of Finance & Controller6yrsVeri yokVeri yok
4.2yrs
Ortalama Görev Süresi
54.5yo
Ortalama Yaş

Deneyimli Yönetim: ACER 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.2 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Christopher Schelling
Founder6.2yrsUS$834.28k11.09%
$ 2.2m
Stephen Aselage
Independent Chairman of the Board6.2yrsUS$104.95k1.98%
$ 389.2k
Michelle Griffin
Independent Director6.2yrsUS$88.08k0%
$ 0
Stuart J. Swiedler
Member of the Scientific Advisory Boardno dataVeri yokVeri yok
John Dunn
Independent Director6.2yrsUS$84.95k0.11%
$ 22.0k
Thomas Fleming
Member of the Scientific Advisory Boardno dataVeri yokVeri yok
Jason Amello
Independent Director6.2yrsUS$83.08k0%
$ 0
Marlene Haffner
Member of the Scientific Advisory Boardno dataVeri yokVeri yok
Gerard Berry
Member of the Scientific Advisory Boardno dataVeri yokVeri yok
6.2yrs
Ortalama Görev Süresi
66yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: ACER 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.2 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2023/11/20 12:43
Gün Sonu Hisse Fiyatı2023/11/17 00:00
Kazançlar2023/06/30
Yıllık Kazançlar2022/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Acer Therapeutics Inc. 8 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Kumaraguru RajaBrookline Capital Markets
Constantine DavidesD. Boral Capital LLC.
Vernon BernardinoH.C. Wainwright & Co.